| abstract |
The invention describes new compounds as pharmaceutical active substances, which have, in vitro, a greater affinity for rat prostate estrogen receptor preparations than for rat uterus estrogen receptor preparations, in vivo, present a preferential action in bones, in comparison with that developed in the uterus and / or a pronounced action from the point of view of the stimulation of the expression of the receptor and the 5HT2a transporter. The invention also relates to the elaboration and therapeutic use of these new compounds, as well as to the forms of pharmaceutical administration that contain them. The new compounds are 16alpha and 16beta-hydroxy-estra-1,3,5 (10) -estratriennes that carry other substituents in their steroid structure, as well as they can have one or more additional double bonds in rings B, C and / or D. |